Friday, April 10, 2026 – Friday, April 10 - By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.
Friday, April 10, 2026 – Friday, April 10 - → A decorated GLP-1 pioneer is retiring at Novo Nordisk.
Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the ...
Friday, April 10, 2026 – Friday, April 10 - Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.
Thursday, April 9, 2026 – Friday, April 10 - Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.
Thursday, April 9, 2026 – Friday, April 10 - (MedPage Today) -- Integrating the most effective obesity treatments into cancer survivorship offers "an unprecedented opportunity" to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in...
Thursday, April 9, 2026 – Friday, April 10 - The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout
Thursday, April 9, 2026 – Friday, April 10 - Steve Ubl, chief executive of PhRMA, plans to step down at the end of the year, after more than a decade leading the main trade group for brand-name drug makers
Wednesday, April 8, 2026 – Thursday, April 9 - 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individuals lose less than 5% of their body weight, whereas others lose more than 20%. Some individuals experience side effects such as nausea and vomiting, whereas others do not.
Wednesday, April 8, 2026 – Thursday, April 9 - Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the drugs will cause nausea or vomiting.
Wednesday, April 8, 2026 – Thursday, April 9 -